Expanded Access Program of Surufatinib

Exclusion Criteria

• •1. Uncontrollable hypertension, as defined by local institution
• •2. Gastrointestinal disease or condition that the physician suspects may affect drug absorption
• •3. History or presence of a serious hemorrhage
• •4. Clinically significant cardiovascular disease
• •5. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy
• •6. High risk of bleeding at screening due to tumor invasion
• •7. Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing or thromboembolic events (including stroke and/or transient ischemic attack) within 6 months prior to first dosing
• •8. Received treatment with anticancer therapy, including investigational therapy, within 7 days or 5 half-lives (whichever is longer)
• •9. Received prior treatment with surufatinib
• •10. Inability to take medication orally
• •11. Any other clinically significant comorbidities that, in the judgment of the treating physician, could predispose the patient to safety risks